Q/C Technologies (QCLS) Q1 2026 earnings summary

Executive summary

• Shifted strategic focus from pharmaceuticals to energy-efficient blockchain and quantum-class laser-based computing, leveraging an exclusive global license with LightSolver Ltd. for the qc-LPU100 platform.

• Evaluating divestiture of legacy pharmaceutical assets (Isomyosamine and Supera-CBD) to fund new initiatives.

• No product revenue generated; operations funded primarily through equity sales and warrant exercises.

Financial highlights

• Net loss attributable to common stockholders was $1.53 million for Q1 2026, compared to $1.94 million in Q1 2025.

• Operating loss for Q1 2026 was $1.86 million, down from $2.47 million in Q1 2025.

• Cash on hand at March 31, 2026 was $1.13 million; marketable securities totaled $11.85 million.

• Working capital stood at $10.02 million; stockholders’ equity was $20.72 million with an accumulated deficit of $145.65 million.

• Cash used in operating activities for Q1 2026 was $3.29 million.

Outlook and guidance

• Management believes current financial resources are sufficient to fund operations and contractual obligations for at least the next twelve months.

• Substantial additional funding will be needed to support ongoing operations and growth strategy, especially for laser-based computing development.

• No meaningful revenue expected until successful development and commercialization of laser-based computing products.